跳至主要内容
临床试验/NCT01470352
NCT01470352已完成不适用

Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention

d_yarnitsky1 个研究点 分布在 1 个国家目标入组 179 人开始时间: 2011年11月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
179
试验地点
1
主要终点
Therapeutic response to the analgesic drugs

研究概览

简要总结

To delineate brain mechanisms that subserve EA in the healthy state and to identify alterations in mechanisms supporting EA in chronic pain and their therapeutic relevance. Individuals with migraine will be examined between episodes in order to assess basal alterations in the efficiency of spatial and temporal filtering of noxious information. This population provides the unique opportunity to examine such processes without confounds arising from ongoing pain.

详细描述

Pain is a uniquely individual experience that is powerfully shaped by the action of descending control mechanisms. These systems may play crucial roles in the moment-to-moment tuning of the sensitivity, spatial, and temporal response characteristics of nociceptive processing mechanisms during both acute and pathological pain states. However, these systems remain poorly understood in human subjects. The proposed research will use psychophysics and multiparametric MRI to (i) delineate the brain mechanisms that subserve and regulate endogenous analgesia (EA) in the healthy state and (ii) to identify alterations in mechanisms supporting EA in chronic pain and their therapeutic relevance. In both healthy subjects and chronic pain patients, EA will be probed using the DNIC (diffuse noxious inhibitory controls) and offset analgesia paradigms. Functional MRI will examine activation of brainstem mechanisms important in EA, while both functional and structural connectivity analyses will assess the regulation of these brainstem mechanisms by cerebral cortical regions involved in attention and affect. One pathological painful condition, migraine, will be examined since it allows changes in EA associated with chronic pain to be investigated between episodes of pain. Finally, EA and EA associated structural and functional parameters will be used to predict the efficacy of one compound, amitriptyline, to treat migraine in individual patients. Taken together, the proposed research will provide substantial insights into basic mechanisms supporting and regulating EA and can provide a foundation for mechanism-based individualized choice of therapy that may benefit all chronic pain patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • patients diagnosed with migraine based on the International Headache Society (IHS) criteria 1 that have >4 attacks/month, both with and without aura

排除标准

  • patients receiving any migraine preventive treatment during last 3 months or prior treatment with amytriptiline
  • other chronic pain conditions
  • psychiatric, other neurological diseases, language barrier or cognitive dysfunction

研究组 & 干预措施

treatment

Active Comparator

Duloxetine will be given in a daily dose of 30 mg for 5 weeks

干预措施: Placebo (Drug)

Placebo

Placebo Comparator

干预措施: Doluxetine (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

treatment

Active Comparator

Duloxetine will be given in a daily dose of 30 mg for 5 weeks

干预措施: Doluxetine (Drug)

结局指标

主要结局

Therapeutic response to the analgesic drugs

时间窗: 2 month

The level of pain relief

次要结局

未报告次要终点

研究者

发起方
d_yarnitsky
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

d_yarnitsky

Head of Neurology Department

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验